The global insulin delivery pen market is estimated to record a CAGR of 8.1% from 2024 to 2034. This is likely to take the market value from an estimated USD 26,408.7 million in 2024 to a projected ...

Go-Pen ApS announced recently that it received FDA 510(k) clearance for its Go-Pen cost-effective, user-filled insulin pen.

Smart insulin pens & pumps market to hit USD 14.6 Bn by 2035, fueled by diabetes tech innovation, remote monitoring, and patient-centric insulin delivery systems.

Ellison says the settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba, Fiasp, and Novolin, at any formulation and via any delivery method—at $35 per monthly ...

By Estelle Timar-Wilcox and Alex Haddon Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three major drug manufacturers ...

On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over ...

Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three major drug manufacturers.

Novo Nordisk is phasing out human insulin pens to focus on its newer diabetes and obesity medicines, sparking protests and concerns over access in low-income countries. Modern insulin, preferred in ...

Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has drawn criticism for leaving many reliant on human insulin, especially in low ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.